OCULAR THERAPEUTIX, INC (OCUL)
A
Pipeline Grade
Financial Position (from SEC Filings)
$668.3M
Cash & Equivalents
$66.0M
Quarterly Burn Rate
30 mo
Est. Cash Runway
$1,870M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
DEXAMETHASONE
DEXTENZA |
NDA | Adverse Events, Allergic Conjunctivitis, Bilateral Conjunctivitis (Disorder), Cataract, Cataract Surgery, Cataract Surgery Incision Leak, Chronic Allergic Conjunctivitis, Collagen Crosslinking, Diabetic Macular Edema, Dry Eye, Dry Eye Disease, Dry Eye Syndromes, Endophthalmitis, Eye Diseases, Glaucoma, Glaucoma Following Surgery, Glaucoma Surgery, Graft vs Host Disease, Healthy, Healthy Subjects, Keratoconus, Unstable, Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD), Non-infectious Anterior Uveitis, Non-proliferative Diabetic Retinopathy, Ocular Disease Requiring Surgery, Ocular Hypertension, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Injury, Ocular Surface Disease, Open Angle Glaucoma and Ocular Hypertension, Open-angle Glaucoma, Patient Preference, Post Ocular Surgical Inflammation and Pain, Post Operative Pain, Post-Operative Inflammation, Post-Surgical Ocular Inflammation, Post-Surgical Ocular Pain, Postoperative Pain, Pterygium, Refractive |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04371445 | Dextenza in the Post-op Management of Vitreoretinal Surgeries | PHASE4 | Recruiting | 30 |
| NCT06223958 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects Wi... | PHASE3 | Active Not Recruiting | 344 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.